Stereoselectivity in the pharmacodynamics and pharmacokinetics of the chiral antimalarial drugs.
Several of the antimalarial drugs are chiral and administered as the racemate. These drugs include chloroquine, hydroxychloroquine, quinacrine, primaquine, mefloquine, halofantrine, lumefantrine and tafenoquine. Quinine and quinidine are also stereoisomers, although they are given separately rather than in combination. From the perspective of antimalarial activity, most of these agents demonstrate little stereoselectivity in their effects in vitro. Mefloquine, on the other hand, displays in vitro stereoselectivity against some strains of P. falciparum, with a eudismic ratio of almost 2 : 1 in favour of the (+)-enantiomer. Additionally, for some of these agents (e.g. halofantrine, primaquine, chloroquine), stereoselectivity has been noted in the ability of the enantiomers to cause certain adverse effects. In recent years, stereospecific analytical methods capable of measuring the individual enantiomers after the administration of racemic drugs have been reported for a number of chiral antimalarial drugs. These assays have revealed that almost all the studied antimalarial drugs display stereoselectivity in their pharmacokinetics, leading to enantioselectivity in their plasma concentrations. Whereas the oral absorption of these agents appears to be non-stereoselective, stereoselectivity is often seen in their volume of distribution and/or clearance. With regard to distribution, plasma protein binding of some chiral antimalarial drugs exhibits a significant degree of stereoselectivity, leading to stereoselective distribution to blood cells and other tissues. Because of their low hepatic extraction ratios, stereoselective plasma protein binding also contributes to the stereoselectivity in the metabolism of these drugs. Chiral metabolites are formed from some parent antimalarial drugs, although stereoselective aspects of the pharmacokinetics of the metabolites are not well understood. It is concluded that knowledge of the stereoselective aspects of these agents may be helpful in better understanding their mechanisms of action and possibly optimising their clinical safety and/or effectiveness.
Brocks
Dion R
DR
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada. DBROCKS@pharmacy.ualberta.ca
Mehvar
Reza
R
D000818:Animals; D000962:Antimalarials / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D019540:Area Under Curve; D002986:Clinical Trials as Topic; D006207:Half-Life; D006801:Humans; D007408:Intestinal Absorption; D008288:Malaria / Q000145:classification / Q000188:drug therapy* / Q000378:metabolism; D008657:Metabolic Clearance Rate; D010961:Plasmodium / Q000187:drug effects / Q000254:growth & development / Q000472:pathogenicity; D013237:Stereoisomerism; D013329:Structure-Activity Relationship; D014018:Tissue Distribution
D000962:Antimalarials